STEP-3 (JAMA 2021) tested semaglutide 2.4 mg with intensive behavioral therapy in 611 adults. Mean weight loss at 68 weeks: 16.0% in semaglutide+IBT vs 5.7% placebo+IBT.
STEP-3, published in JAMA in 2021, tested whether adding semaglutide 2.4 mg to an intensive behavioral therapy (IBT) program produced incremental weight loss compared with IBT alone. In 611 adults with overweight or obesity, semaglutide+IBT achieved 16.0% mean weight loss at 68 weeks versus 5.7% in placebo+IBT¹. STEP-3 quantifies the marginal weight-loss benefit of adding pharmacotherapy to maximally implemented behavioral treatment.
Trial design
STEP-3 (Wadden et al., JAMA 2021) was a 68-week randomized, double-blind, placebo-controlled trial in 611 adults with BMI ≥30 or ≥27 with comorbidity, without diabetes¹. Randomized 2:1 to once-weekly semaglutide 2.4 mg or placebo, both with IBT: 30 counseling sessions over 68 weeks plus low-calorie meal-replacement (1,000-1,200 kcal/day) for the first 8 weeks. The behavioral intervention was substantially more intensive than STEP-1's ~17 sessions of standard counseling, isolating the marginal contribution of semaglutide on top of best-practice behavioral treatment.
Primary outcomes
At week 68, mean weight change was -16.0% in semaglutide+IBT vs -5.7% in placebo+IBT (treatment difference -10.3 percentage points; 95% CI -12.0 to -8.6; P<0.001)¹. Proportion achieving ≥5% weight loss: 86.6% vs 47.6%. Higher thresholds: 75.3% vs 27.0% (≥10%), 55.8% vs 13.2% (≥15%), 35.7% vs 3.7% (≥20%).
Power of intensive behavioral therapy
The 5.7% mean weight loss in placebo+IBT is notable: approximately double the 2.4% in the STEP-1 placebo arm where lifestyle was less intensive¹². Maximally implemented behavioral therapy with low-calorie meal-replacement produces meaningful weight loss itself.
The incremental semaglutide effect over this intensive behavioral foundation was ~10 percentage points — similar in magnitude to the semaglutide effect over standard counseling in STEP-1. Pharmacologic and behavioral effects appear largely additive rather than competing.
Cardiometabolic outcomes
Improvements in waist circumference, systolic BP, fasting glucose, lipids, and patient-reported quality of life were larger in semaglutide+IBT than placebo+IBT, consistent with greater weight loss. HbA1c decreased 0.4 percentage points in semaglutide+IBT vs 0.1 in placebo+IBT¹.
Clinical implications
STEP-3 supports two conclusions: (1) intensive behavioral therapy with structured meal replacement is itself a powerful intervention and is not made obsolete by pharmacotherapy; (2) when intensive behavioral therapy is available, adding semaglutide approximately triples mean weight loss (from 5.7% to 16.0%).
For patients without access to intensive behavioral programs (most clinical settings), STEP-1 results (14.9% on standard counseling) remain the more relevant reference. STEP-3 represents an upper bound achievable with maximally integrated behavioral and pharmacologic treatment.
Editor's Pick · #1 of 10
NexLife — Semaglutide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
IBT typically involves 12-30 counseling sessions over 6-12 months covering dietary self-monitoring, behavioral substitution, structured eating, and progressive physical activity. The foundation of evidence-based obesity care.
Is IBT covered by insurance?
Medicare covers obesity IBT by primary care providers (CPT 99403). Commercial coverage varies. Many evidence-based programs (Naturally Slim, Noom, academic centers) are also options.
Do I need IBT with semaglutide?
Per FDA labeling, semaglutide 2.4 mg is indicated as adjunct to reduced-calorie diet and increased physical activity. Some behavioral intervention is required for label compliance and best outcomes.
STEP-3 vs STEP-1?
STEP-1 used standard lifestyle counseling. STEP-3 used much more intensive behavioral therapy and structured low-calorie meal replacement. Semaglutide weight loss was similar (~15-16% in both); the placebo group lost twice as much in STEP-3.
Do meal replacements help?
Structured meal replacement supports calorie control during weight loss and was a component of the STEP-3 protocol. Well-supported for the initial weight-loss phase.
References
Wadden TA, Bailey TS, Billings LK, et al.Effect of Subcutaneous Semaglutide vs Placebo as Adjunct to Intensive Behavioral Therapy on Body Weight: STEP 3.JAMA. 2021;325(14):1403-1413.PMID: 33724399
Wilding JPH, Batterham RL, Calanna S, et al.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1).N Engl J Med. 2021;384(11):989-1002.PMID: 33567185
Wadden TA, Tronieri JS, Butryn ML.Lifestyle modification approaches for the treatment of obesity in adults.Am Psychol. 2020;75(2):235-251.PMID: 32052997
U.S. Food and Drug Administration.Wegovy (semaglutide) injection — Prescribing Information.FDA Drug Approval Records.View source
Citations are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed. FDA links resolve to fda.gov. All citations were last verified 2026-05-11.
SS
Lead Medical Researcher
Dr. Sam Saberian, PharmD
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and clinical trial review.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.